Sitagliptin and oral cancer risk in type 2 diabetes patients

Chin-Hsiao Tseng

1Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Zhunan, Taiwan

Correspondence to: Chin-Hsiao Tseng, email: ccktsh@ms6.hinet.net

Keywords: diabetes mellitus, oral cancer, sitagliptin, Taiwan

ABSTRACT

The reimbursement database of the Taiwan’s National Health Insurance was used to evaluate oral cancer risk after sitagliptin use. Patients newly diagnosed of type 2 diabetes during 1999–2008 were recruited. A 1:1 propensity score matched-pair sample of 39195 ever users and 39195 never users were followed up until December 31, 2011. Cox regression incorporated with the inverse probability of treatment weighting using propensity score was used to estimate hazard ratios. Results showed that the overall hazard ratio was not statistically significant (0.956, 95% confidence interval: 0.652–1.401). However, in tertile analyses, the hazard ratio for the first (< 7.47 months), second (7.47–15.63 months) and third (> 15.63 months) tertile of cumulative duration was 1.563 (0.963–2.537), 1.236 (0.738–2.071) and 0.345 (0.164–0.725), respectively; and was 1.575 (0.963–2.575), 1.224 (0.738–2.033) and 0.347 (0.165–0.731), respectively, for the first (< 19,600 mg), second (19,600–42,200 mg) and third (> 42,200 mg) tertile of cumulative dose. Sensitivity analyses after excluding patients who developed any other cancer during follow-up did not change the results substantially. Additionally, the risk of oral diseases that may predispose to oral cancer (i.e., "gingival and periodontal diseases" and/or "oral mucosal lesions") paralleled the risk pattern of oral cancer, suggesting a possible explanation for the risk change of oral cancer related to sitagliptin. In conclusion, sitagliptin may reduce oral cancer risk when the cumulative duration is > 15.63 months or the cumulative dose is > 42,200 mg.

INTRODUCTION

Incretin-based therapies by using the oral form of dipeptidyl peptidase-4 (DPP-4) inhibitors have become a mainstay in the treatment of type 2 diabetes mellitus. Sitagliptin, probably the most commonly used DPP-4 inhibitor, was the first in the class approved for clinical use in 2006 [1]. There are some concerns on cancer risk related to the use of incretin-based therapies, especially for pancreatic cancer and thyroid cancer [1–3]. On the other hand, some animal and in vitro studies suggested that sitagliptin inhibits the growth of colorectal cancer [1, 4]. A Japanese case report showed that sitagliptin treatment for 3 weeks dramatically regressed hepatocellular carcinoma in a patient with hepatitis C infection [5]. In a recent observational study, sitagliptin reduced the risk of prostate cancer [6].

Whether sitagliptin may increase or decrease the risk of oral cancer has not been investigated. The present study evaluated such risk after sitagliptin use in type 2 diabetes patients by using the reimbursement records in Taiwan’s National Health Insurance (NHI) database. Other incretin-based therapies (including saxagliptin, vildagliptin, linagliptin and alogliptin for DPP-4 inhibitors; and exenatide and liraglutide for glucagon-like peptide 1 receptor agonists) currently available in Taiwan were not evaluated because they were not approved until after mid-2010 [1] and therefore were less commonly used during the study period.
RESULTS

There were 39,195 never users and 39,195 ever users in the matched cohort (Figure 1). Although some variables (i.e., age, hypertension, statin, angiotensin converting enzyme inhibitor/angiotensin receptor blocker, calcium channel blocker, sulfonylurea, insulin, acarbose, rosiglitazone, aspirin and dipyridamole) differed significantly, none had a value of standardized difference > 10% (Table 1). Therefore, the results were unlikely influenced by residual confounding from the differences in these characteristics.

Table 2 shows the incidence rates of oral cancer and hazard ratios by sitagliptin exposure. The respective incident number of oral cancer for never users and ever users was 54 and 52, with respective incidence of 75.68 and 72.38 per 100,000 person-years. The overall hazard ratio of 0.956 (95% confidence interval: 0.652–1.401) suggested a null association. However, when evaluating the distribution of the incident cases of oral cancer by the tertiles of cumulative duration and cumulative dose of sitagliptin therapy, there was a trend of decreasing incidence with longer duration or higher cumulative dose. A significantly reduced risk of approximately 65% was observed for the third tertiles. The results in sensitivity analyses after excluding patients who developed any other cancer during follow-up were very similar and did not change the conclusion of the study.

Table 3 shows the incidence rates of oral diseases including “gingival and periodontal diseases” and/or “oral mucosal lesions” and the hazard ratios by sitagliptin exposure. The findings paralleled those observed for oral cancer and suggested an overall neutral effect. Although the risk was significantly higher for the first and second tertiles of cumulative duration and cumulative dose, the risk reduced to a significant level in patients categorized in the third tertiles.

DISCUSSION

This is the first observational study conducted in humans to evaluate the risk of oral cancer after sitagliptin use in type 2 diabetes patients. Although the risk was neither increased nor decreased in the overall analyses, a significantly lower risk was seen in the third tertiles of cumulative duration and cumulative dose in either the primary analyses or the sensitivity analyses (Table 2). The
risk of oral diseases that may predispose to oral cancer (i.e., “gingival and periodontal diseases” and/or “oral mucosal lesions”) seemed to echo the findings observed for oral cancer (Table 3).

The mechanisms of a reduced risk of oral cancer after sitagliptin use remains to be explored. A recent study suggested that the activity of DPP-4 in the saliva of patients with periodontitis was significantly elevated and positively correlated with all clinical parameters of periodontitis including the prevalence of infection with Porphyromonas gingivalis [7]. Chronic inflammation is a key component of tumor progression in the oral cavity [8]. Diabetes patients suffer from a significantly higher risk of periodontitis [9, 10] and oral cancer [11]. Therefore, a potential mechanism linking a reduced risk of oral cancer after sitagliptin use is through its inhibition of the activity
Table 2: Incidence rates of oral cancer and hazard ratios by sitagliptin exposure

| Sitagliptin use  | Cases followed | Incident cases of oral cancer | Person-years | Incidence rate (per 100,000 person-years) | Hazard ratio | 95% Confidence interval | P-value |
|------------------|----------------|------------------------------|--------------|------------------------------------------|--------------|--------------------------|---------|
| Never users      | 39195          | 54                           | 71353.08     | 75.68                                    | 1.000        | (0.652–1.401)            | 0.8173  |
| Ever users       | 39195          | 52                           | 71839.78     | 72.38                                    | 0.956        | (0.652–1.401)            | 0.8173  |

Cumulative duration (months)

| Never users      | 39195          | 54                           | 71353.08     | 75.68                                    | 1.000        | (0.652–1.401)            | 0.8173  |
| < 7.47           | 13324          | 24                           | 21264.36     | 112.86                                   | 1.563        | (0.963–2.537)            | 0.0708  |
| 7.47–15.63       | 12533          | 20                           | 21879.55     | 91.41                                    | 1.236        | (0.738–2.071)            | 0.4204  |
| > 15.63          | 13338          | 8                            | 28695.87     | 27.88                                    | 0.345        | (0.164–0.725)            | 0.0050  |

Cumulative dose (mg)

| Never users      | 39195          | 54                           | 71353.08     | 75.68                                    | 1.000        | (0.652–1.401)            | 0.8173  |
| < 19,600         | 12716          | 23                           | 20366.50     | 112.93                                   | 1.575        | (0.963–2.575)            | 0.0703  |
| 19,600–42,200    | 13135          | 21                           | 22845.36     | 91.92                                    | 1.224        | (0.738–2.033)            | 0.4335  |
| > 42,200         | 13344          | 8                            | 28627.92     | 27.94                                    | 0.347        | (0.165–0.731)            | 0.0053  |

Sensitivity analyses after excluding patients who developed any other cancer during follow-up

| Never users      | 38256          | 52                           | 69499.80     | 74.82                                    | 1.000        | (0.634–1.388)            | 0.7486  |
| Ever users       | 38180          | 49                           | 69916.09     | 70.08                                    | 0.938        | (0.634–1.388)            | 0.7486  |

Cumulative duration (months)

| Non-users        | 38256          | 52                           | 69499.80     | 74.82                                    | 1.000        | (0.905–2.471)            | 0.1161  |
| < 7.47           | 12927          | 22                           | 20617.51     | 106.71                                   | 1.496        | (0.905–2.471)            | 0.1161  |
| 7.47–15.63       | 12223          | 20                           | 21296.44     | 93.91                                    | 1.284        | (0.764–2.157)            | 0.3445  |
| > 15.63          | 13030          | 7                            | 28002.15     | 25.00                                    | 0.313        | (0.142–0.689)            | 0.0040  |

Cumulative dose (mg)

| Non-users        | 38256          | 52                           | 69499.80     | 74.82                                    | 1.000        | (0.902–2.505)            | 0.1175  |
| < 19,600         | 12326          | 21                           | 19725.73     | 106.46                                   | 1.503        | (0.902–2.505)            | 0.1175  |
| 19,600–42,200    | 12824          | 21                           | 22266.16     | 94.31                                    | 1.269        | (0.762–2.113)            | 0.3595  |
| > 42,200         | 13030          | 7                            | 27924.19     | 25.07                                    | 0.316        | (0.143–0.695)            | 0.0042  |

of DPP-4 in oral mucosa. The findings in Table 3 showing a significantly reduced risk of oral diseases after prolonged use of sitagliptin provided a support for this explanation. Anagliptin, a DPP-4 inhibitor, facilitated the restoration of mucosal damage in a model of experimental murine colitis [12]. An in vitro study also showed promising anti-cancer activity of sitagliptin and vildagliptin on colon cancer cell lines (HT-29), with sitagliptin more potent than vildagliptin [13]. Sitagliptin also corrected the dysbiosis of gut microbiota in a rat model [14]. Although DPP-4 activity in the oral mucosa of patients with oral cancer remains unknown, it might also be high as observed in patients with periodontitis [7]. It is worthwhile to investigate such enzyme activity in these patients and to see whether DPP-4 inhibitors may prevent the development of or have a therapeutic role on oral cancer.
Smoking, alcohol drinking and betel nut chewing are recognized risk factors of oral cancer [15, 16]. However, we were not able to evaluate their potential confounding effects due to the lack of information in the NHI database. A confounder should both be correlated with the exposure (sitagliptin use) and the outcome (oral cancer), and should not be an intermediate between exposure and outcome [17]. Because of the lack of significant difference in the distribution of chronic obstructive pulmonary disease (a surrogate for smoking), tobacco abuse and alcohol-related diagnoses between ever and never users of sitagliptin (Table 1), and because betel nut chewers are always smokers in Taiwan [18–20], we have no reason to believe that these factors can play important role as confounders.

Human papillomavirus may also play an important role in oral cancer [21], especially in women [22]. However, this infection was not considered in the analysis because only 8 patients were identified with such a diagnosis. The small case number did not allow any analysis with sufficient power. Therefore, potential confounding effect of this viral infection requires further investigation.

This study has several strengths. The database covers almost the whole population and keeps all claims records from outpatient visits and hospital admission. Therefore, the findings in the present study can be readily generalized to the whole population. With the use of medical records, self-reporting bias can also be limited. The present study also suffers from less bias from different detection rates of oral cancer or other comorbidities among different social classes because of the following reasons. First, the Bureau of NHI considers cancer as a severe morbidity and patients with a cancer diagnosis are waived of most medical co-payments. Second, the drug cost-sharing is low or can be waived for patients with certain conditions including low-income household, veterans and prescription refills for chronic disease.

Study limitations may include a lack of actual measurement data of smoking and alcohol drinking, and the lack of information of other confounders such as betel nut chewing, lifestyle, diet, family history, and genetic parameters. The impact of glycemic control and the role of the pathology, grading and staging of oral cancer could not be evaluated because these data are not available in the database. Finally, whether the findings of the present study can be generalized to other DPP-4 inhibitors or to glucagon-like peptide 1 receptor agonists require further investigation.

| Sitagliptin use  | Cases followed | Incident cases of oral diseases | Person-years | Incidence rate (per 100,000 person-years) | Hazard ratio | 95% Confidence interval | P-value |
|------------------|----------------|-------------------------------|--------------|------------------------------------------|-------------|------------------------|--------|
| Never users      | 4764           | 610                           | 8169.96      | 7466.38                                  | 1.000       | (0.892–1.118)          | 0.9797 |
| Ever users       | 4764           | 616                           | 8275.77      | 7443.41                                  | 0.999       | (0.892–1.118)          | 0.9797 |

| Cumulative duration (months) | Cases followed | Incident cases of oral diseases | Person-years | Incidence rate (per 100,000 person-years) | Hazard ratio | 95% Confidence interval | P-value |
|-----------------------------|----------------|-------------------------------|--------------|------------------------------------------|-------------|------------------------|--------|
| Non-users                   | 4764           | 610                           | 8169.96      | 7466.38                                  | 1.000       | (0.892–1.118)          | 0.9797 |
| < 6.87                      | 1573           | 278                           | 2385.93      | 11651.65                                 | 1.634       | (1.416–1.885)          | < 0.0001 |
| 6.87–14.93                  | 1532           | 214                           | 2437.67      | 8778.89                                  | 1.214       | (1.038–1.419)          | 0.0154 |
| > 14.93                     | 1659           | 124                           | 3452.18      | 3591.94                                  | 0.446       | (0.368–0.542)          | < 0.0001 |

| Cumulative dose (mg) | Cases followed | Incident cases of oral diseases | Person-years | Incidence rate (per 100,000 person-years) | Hazard ratio | 95% Confidence interval | P-value |
|----------------------|----------------|-------------------------------|--------------|------------------------------------------|-------------|------------------------|--------|
| Non-users            | 4764           | 610                           | 8169.96      | 7466.38                                  | 1.000       | (0.892–1.118)          | 0.9797 |
| < 17,600             | 1569           | 269                           | 2376.27      | 11320.26                                 | 1.591       | (1.377–1.838)          | < 0.0001 |
| 17,600–40,500        | 1574           | 222                           | 2544.72      | 8723.96                                  | 1.198       | (1.027–1.399)          | 0.0217 |
| > 40,500             | 1621           | 125                           | 3354.79      | 3726.02                                  | 0.464       | (0.383–0.563)          | < 0.0001 |

Oral diseases include “gingival and periodontal diseases” and/or “oral mucosal lesions”
In summary, this study suggests that sitagliptin use may reduce the risk of oral cancer after a cumulative duration of > 15.63 months or a cumulative dose of > 42,200 mg. In parallel, the risk of oral diseases that may predispose to oral cancer also decreases after prolonged use of sitagliptin. Because of the observational nature of the study, additional confirmation is necessary.

MATERIALS AND METHODS

The NHI healthcare system and its reimbursement database in Taiwan have been described in detail in previously published papers [23, 24]. In brief, the NHI is compulsory and covers > 99% of the population and has contracts with > 98% of all hospitals in Taiwan. The database can be used for academic research after review and approval. This study was granted with an approval number 99274.

Disease diagnoses are coded by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) during the study period; and diabetes was coded 250.XX and oral cancer 140, 141, 143, 144, 145, 146, 148, and 149.

Figure 1 shows the procedure in selecting a cohort of 1:1 propensity score (PS) matched-pair sample of sitagliptin ever and never users. Patients were newly diagnosed of type 2 diabetes mellitus at the age of 25–74 years from 1999 to 2008. They should have received prescriptions of antidiabetic drugs for 2 or more times at the outpatient clinic until after March 1, 2009 (the date sitagliptin was approved for reimbursement by the Bureau of NHI). Patients with a diagnosis of diabetes mellitus during 1996–1998 were excluded to assure their diabetes being first diagnosed after 1999. To avoid the potential confounding from other incretin-based therapies that were approved for clinical use during follow-up, users of saxagliptin or vildagliptin (n = 6322) and exenatide (n = 154) were excluded. A total of 522 patients were excluded due to missing data and 3251 patients with type 1 diabetes mellitus (based on the issuance of the so-called “Severe Morbidity Card” after a certified diagnosis) were excluded because incretin-based therapies were not approved for their treatment. Because incretin-based therapies have been reported to increase the risk of congestive heart failure, acute pancreatitis and cancers involving the pancreas and thyroid [1-3, 25, 26], patients who had been diagnosed of any cancer (n = 67603), congestive heart failure (n = 86396) or acute pancreatitis (n = 18209) before entry were also excluded. Patients aged < 25 (n = 3635) or > 75 (n = 80043) years and those followed up for a duration < 180 days (n = 43528) were also excluded. In consideration of an imbalance in characteristics between sitagliptin ever and never users in this original sample, a 1:1 PS matched-pair sample was created using the Greedy 8 ---> 1 digit match algorithm as recommended by Parsons [27]. The PS was derived from all characteristics and the date of entry by logistic regression. This matching method has been used and described in detail in our previous studies [6, 28–31].

Cumulative duration (months) and cumulative dose (mg) of sitagliptin use were calculated and their tertiles were used for analyses. Comorbidities and covariates used in the study included [32–37]: age, diabetes duration, sex, hypertension (ICD-9-CM code: 401–405), chronic obstructive pulmonary disease (a surrogate for smoking; 490–496), stroke (430–438), nephropathy (580–589), ischemic heart disease (410–414), peripheral arterial disease (250.7, 785.4, 443.81 and 440–448), eye disease (250.5, 362.0, 369, 366.41 and 365.44), obesity (278), dyslipidemia (272.0–272.4), acute pancreatitis (577.0), tobacco abuse (305.1, 649.0 and 989.84), alcohol-related diagnoses (291, 303, 535.3, 571.0–571.3, 980.0), gingival and periodontal diseases (523), and oral mucosal lesions (528.6, 528.7, 528.8). Antidiabetic drugs other than sitagliptin and medications commonly used in diabetes patients included insulin, sulfonylurea, metformin, meglitinide, acarbose, pioglitazone, rosiglitazone, statin, fibrate, angiotensin converting enzyme inhibitor/angiotensin receptor blocker, calcium channel blocker, aspirin, ticlopidine, clopidogrel and dipyridamole. These characteristics between never and ever users of sitagliptin were compared by Student’s t test for age and diabetes duration and by Chi-square test for other variables.

The incidence density of oral cancer was calculated for different subgroups of sitagliptin exposure, i.e., for never users, ever users and tertiles of cumulative duration and cumulative dose. The numerator of the incidence density was the case number of new-onset oral cancer during follow-up. The denominator was calculated from the person-years of follow-up, which ended at the time of a new diagnosis of oral cancer, on the date of the last reimbursement record, or on December 31, 2011.

Hazard ratios comparing different subgroups of sitagliptin exposure to never users were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS [38]. Because sitagliptin may increase or decrease the risk of some other cancers [1–6], sensitivity analyses were conducted after excluding patients who developed other cancers during follow-up. To examine whether sitagliptin might also increase or decrease the risk of oral diseases that may predispose to oral cancer, the incidence of “gingival and periodontal diseases” and/or “oral mucosal lesions” and hazard ratios were also calculated. These analyses were conducted in a PS-matched cohort of ever and never users of sitagliptin who did not have these oral diseases at entry.

SAS statistical software, version 9.3 (SAS Institute, Cary, NC), was used for statistical analyses. A P-value < 0.05 was considered as statistically significant.
ACKNOWLEDGMENTS

The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.

CONFLICTS OF INTEREST

The author declares no conflicts of interest.

FUNDING

The study was supported by the Ministry of Science and Technology (MOST 103-2314-B-002-187-MY3) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015; 33:67–124.
2. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2016; 46:70–79.
3. Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:24871–9.
4. Femia AP, Raimondi L, Maglieri G, Lodovici M, Mannucci E, Caderni G. Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1, 2-dimethylhydrazine-induced rats. Int J Cancer. 2013; 133:2498–503.
5. Yamamoto S, Tokuhara T, Nishikawa M, Nishizawa S, Nishioka T, Nozawa A, Takahashi A, Watanabe Y, Wada R, Wakasa K, Kubo S. Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: possibly responsible for immune system. Kanzo. 2012; 53:164–7.
6. Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget. 2017; 8:19057–19064.
7. Aemaimanan P, Sattayasai N, Wara-asawapati N, Pitiphat W, Suwannarong W, Prajanee S, Taiweechaisupapong S. Alanine aminopeptidase and dipeptidyl peptidase IV in saliva of chronic periodontitis patients. J Periodontol. 2009; 80:1809–14.
8. Sahingur SE, Yeudall WA. Chemokine function in periodontal disease and oral cavity cancer. Front Immunol. 2015; 6:214.
25. Tseng CH. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget. 2016; 7:62687–96.
26. Tseng CH. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan. Ann Med. 2015; 47:561–9.
27. Parsons LS. Performing a 1:N case-control match on propensity score. http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CBsQFjAAAhUKEwibi7HllcnAhUDoJQKHVeZAA9A&url=http%3A%2F%2Fwww2.sas.com%2Fproceedings%2Fsugi29–29. pdf&usg=AFQjCNFOHGWYu8E8bn4–Bo1TUjJKfT987Q (last accessed January 18, 2017).
28. Tseng CH. Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget. 2016; 7:59548–59555.
29. Tseng CH. Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus. Oncotarget. 2017; 8:18802–18810.
30. Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus. Oncotarget. 2017. doi: 10.18632/oncotarget.17066. [Epub ahead of print].
31. Tseng CH. Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. Diabetes Metab. 2017; S1262–3636:30059–9. doi: 10.1016/j.diabet.2017.03.004. [Epub ahead of print].
32. Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015; 138:147–53.
33. Tseng CH. Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese. BMC Cancer. 2015; 15:41.
34. Tseng CH. Pioglitazone and oral cancer risk in patients with type 2 diabetes. Oral Oncol. 2014; 50:98–103.
35. Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study. PLoS One. 2014; 9:e101553.
36. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80.
37. Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One. 2014; 9:e109832.
38. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013; 32:2837–49.